IVERIC bio. has filed a patent for a method to treat or prevent idiopathic polypoidal choroidal vasculopathy using a combination of Zimura™ (anti-C5 agent) and Eylea® (VEGF antagonist) through intravitreal injections. The treatment involves an initial induction phase followed by a maintenance phase with monthly anti-C5 agent administration. GlobalData’s report on IVERIC bio gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights IVERIC bio Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on IVERIC bio, Peptide pharmacophores was a key innovation area identified from patents. IVERIC bio's grant share as of January 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20240000889A1) outlines a method for treating or preventing idiopathic polypoidal choroidal vasculopathy (IPCV) by administering an anti-C5 agent and a VEGF antagonist to a subject in need. The method involves two administration periods - an induction phase followed by a maintenance phase where only the anti-C5 agent is administered monthly. The administering occurs once every month for at least three consecutive months, with specific dosing schedules outlined for both agents.

The patent specifies the use of specific anti-C5 agents, such as avacincaptad pegol, and VEGF antagonists like ranibizumab, bevacizumab, pegaptanib sodium, tivozanib, ESBA1008, or aflibercept, administered intravitreally in specified amounts. The method also includes details on additional dosing, timing of administration, and the transition from the first to the second administration period. The patent provides a structured approach to effectively treat or prevent IPCV, highlighting the importance of the combination of anti-C5 agents and VEGF antagonists in the management of this condition.

To know more about GlobalData’s detailed insights on IVERIC bio, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies